Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Search
Big Little Things in cancer: small things, big impacts
Little things can be a big deal when you are living with or treating cancer. Sometimes the small things are the most powerful.
"To join Boehringer Ingelheim was the best ever decision"
Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.
Learning and development
We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Employees empower small dairy producers
Boehringer Ingelheim social intrapreneurship helps farmers improve animal welfare and the well-being of rural communities in Southern India.
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Our Asthma Products
Our Asthma Products
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Careers
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
Ukraine Help: The heroes of Mainz-Finthen
Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.
Thelaziosis dog eyeworms
Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
Patient safety your career opportunity
Discover a role in Patient Safety
Our Partners Bioharmony
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Generalized pustular psoriasis: The Impact Beyond The Skin
An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health
Lifelong learning at our Virtual Campus
The Virtual Campus of our Boehringer Ingelheim University supports our employees in their personalized lifelong learning.
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial